Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans

Area of Science:

• Oncology
• Pharmacology
• Clinical Pharmacy

Background:

• Sarcoma treatment often involves high-dose chemotherapy.
• Ifosfamide (IFO) is a commonly used chemotherapeutic agent.
• Understanding ifosfamide pharmacokinetics is crucial for optimizing treatment and minimizing toxicity.

Purpose of the Study:

• To investigate the pharmacokinetic profile of high-dose ifosfamide (IFO) in sarcoma patients.
• To evaluate the effect of phenobarbital (PB) co-administration on ifosfamide pharmacokinetics.
• To determine if ifosfamide kinetics are stationary over a 3-day infusion period.

Main Methods:

• Ten sarcoma patients received high-dose ifosfamide (4 g/m2) via i.v. infusion over 3 days every 4 weeks.
• Phenobarbital (60 mg/day p.o.) was administered on days 1-3 of ifosfamide infusion starting from the second course.
• Ifosfamide pharmacokinetic studies were conducted on the first and third day of each treatment course.

Main Results:

• A statistically significant difference in ifosfamide pharmacokinetic parameters was observed between day 1 and day 3 of each course, irrespective of phenobarbital co-administration.
• The area under the curve for ifosfamide decreased from day 1 to day 3, indicating non-stationary kinetics.
• No significant difference in pharmacokinetic parameters was found when comparing all first days versus all third days across courses.
• Concomitant phenobarbital administration did not influence ifosfamide pharmacokinetics within the described schedule.

Conclusions:

• High-dose ifosfamide exhibits non-stationary pharmacokinetics during a 3-day infusion in sarcoma patients.
• The observed decrease in ifosfamide exposure over the 3 days suggests potential for altered efficacy or toxicity.
• Phenobarbital, at the tested dose and schedule, does not appear to modify ifosfamide pharmacokinetics in this patient population.